U266/iRFP cells are derived from the human myeloma U266 cell line by stably integration of a constitutive miRFP670 stably expression construct. The U266 cells are an important tool in studying the pathogenesis, progression, and treatment of multiple myeloma, as well as for testing chemotherapies and immunotherapies, including monoclonal antibodies, immune checkpoint inhibitors, and CAR-T cell therapies. U266/iRFP cells stably express miRFP670, can be used for in vitro assays and in vivo imaging.
